Results 231 to 240 of about 6,268,728 (387)

The effect of muscle length on the energy for maintenance of tension

, 1933
Wallace O. Fenn, W. B. Latchford
openalex   +1 more source

Whitepaper: Defining and investigating cognitive reserve, brain reserve, and brain maintenance

Alzheimer's & Dementia, 2018
Y. Stern, E. Arenaza‐Urquijo, D. Bartrés-Faz, S. Belleville, Marc Cantilon, G. Chételat, M. Ewers, N. Franzmeier, G. Kempermann, W. Kremen, O. Okonkwo, N. Scarmeas, Anja Soldan, Chinedu Udeh-Momoh, M. Valenzuela, P. Vemuri, E. Vuoksimaa, Eider M. Arenaza Urquiljo, M. Cantillon, S. Clouston, A. Estanga, B. Gold, C. Habeck, Richard N. Jones, Renata Kochhann, W. Kremen, Y. Lim, P. Martínez-Lage, S. Morbelli, R. Ossenkoppele, C. Pettigrew, A. Rosen, Xiaowei Song, A. C. V. Loenhoud   +33 more
semanticscholar   +1 more source

BMP antagonist CHRDL2 enhances the cancer stem‐cell phenotype and increases chemotherapy resistance in colorectal cancer

Molecular Oncology, EarlyView.
Overexpression of CHRDL2 in colon cancer cells makes them more stem‐like and resistant to chemo‐ and radiotherapy. CHRDL2‐high cells have upregulation of the WNT pathway, genes involved in the DNA damage response (DDR) pathway and epithelial‐to‐mesenchymal transition (EMT). This leads to quicker repair of damaged DNA and more cell migration.
Eloise Clarkson, Annabelle Lewis
wiley   +1 more source

A learning-driven algorithm for maintenance team and UAV collaboration in restoring power network. [PDF]

Sci Rep
Pan T, Zheng L, Xu Y, Zhang X, Zhong C, Wang Z.   +5 more
europepmc   +1 more source

Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis

Molecular Oncology, EarlyView.
TRIM24 and TRIM28 are androgen receptor (AR) coregulators which exhibit increased expression with cancer progression. Both TRIM24 and TRIM28 combine to influence the response of castrate‐resistant prostate cancer (CRPC) cells to AR inhibitors by mediating AR signalling, regulation of MYC and upregulating VEGF to promote angiogenesis. Castrate‐resistant
Damien A. Leach, Nilesh Chatterjee, Kellie Spahr, Gilberto Serrano de Almeida, Anabel Varela‐Carver, Taimur T. Shah, Mathias Winkler, Hashim U. Ahmed, Charlotte L. Bevan   +8 more
wiley   +1 more source

Comparison of deep learning models for predictive maintenance in industrial manufacturing systems using sensor data. [PDF]

Sci Rep
Li W, Li T.
europepmc   +1 more source

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

Molecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner, Markus Eckstein, Christoph Mark, Matthias W. Beckmann, Arndt Hartmann, Pamela L. Strissel, Reiner Strick   +6 more
wiley   +1 more source

Variation in Kidney Transplant Referral, Living Donor Contacts, Waitlisting, and Kidney Transplant Across Regional Renal Programs in Ontario, Canada: A Population-Based Cohort Study. [PDF]

Can J Kidney Health Dis
Naylor KL, Yohanna S, Smith G, Garg AX, Elliott L, Knoll G, Kim SJ, Weir M.   +7 more
europepmc   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

Cost-effectiveness analysis of capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy. [PDF]

Ann Med
Liu T, Yao R, Tong Z, Dong M, Zhong L.
europepmc   +1 more source